Edgar Filing: CORTEX PHARMACEUTICALS INC/DE/ - Form 4

CORTEX Pl Form 4 April 21, 20	HARMACEUTIC	CALS INC	C/DE/								
<u> </u>									OMB AF	PROVAL	
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549								OMMISSION	OMB Number:	3235-0287	
if no long subject to Section 1 Form 4 o Form 5 obligatio may cont	Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940							January 31, 2005 Estimated average burden hours per response 0.5			
(Print or Type I	Responses)										
Purcell Richard David Jr. S					I Ticker or Tra RMACEUTI []	-	Ι	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
		Middle) C., 126		f Earliest Tr Day/Year) (014	ransaction			Director _X Officer (give to below) SVP - Resear		Owner or (specify	
				endment, Da nth/Day/Year	ate Original r)		6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person				
GLEN ROO	CK, NJ 07452						-	Form filed by Mo Person			
(City)	(State)	(Zip)	Tab	le I - Non-I	Derivative Sec	urities	s Acqui	ired, Disposed of,	or Beneficial	y Owned	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)		Date, if	3. Transactic Code (Instr. 8)	4. Securities A our Disposed of (Instr. 3, 4 and	of (D)	red (A)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Common Stock	10/15/2014			Code V A	Amount 2,000,000	(D) A	Price \$ 0 (1)	2,000,000	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. onNumber of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		ate	7. Titl Amou Under Secur (Instr.	int of rlying	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secur Bene Owna Follo Repo Trans (Instr
			Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

Edgar Filing: CORTEX PHARMACEUTICALS INC/DE/ - Form 4

Reporting Owners

Reporting Owner Name / Address		Relationships						
in porting of the			10% Owner	Officer	Other			
Purcell Richard David Jr. C/O CORTEX PHARMACEUTICALS, INC. 126 VALLEY ROAD, SUITE C GLEN ROCK, NJ 07452				SVP - Research and Development				
Signatures								
/s/ Richard D. Purcell, Jr.	04/16/2015							
<u>**</u> Signature of Reporting Person	Date							

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Grant of restricted shares for no consideration. The shares vest in four equal installments on January 15, 2015, April 15, 2015, July 15, 2015, and October 15, 2015.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.